Supplemental table 1. Prevalence of any and late age-related macular degeneration (AMD) stratified by diabetes, use of anti-diabetic drugs, hyperlipidemia, and use of lipid-lowering drugs (LLD).

Study	Any AMD							
	No diabetes	Diabetes	No anti-diabetic drugs	Anti-diabetic drugs	No hyperlipidemia	Hyperlipidemia	No LLD	LLD
NICOLA	20.60%	21.40%	20.90%	16.90%	22.40%	20.50%	20.60%	20.90%
AugUR	52.10%	47.50%	52.50%	44.50%	N/A	N/A	53.10%	47.60%
EYERISK	26.80%	26.40%	24.90%	25.30%	40.60%	41.90%	28.80%	25.70%
UEMS	14.60%	10.50%	14.40%	10.10%	N/A	N/A	14.40%	13.20%
LIFE*	38.20%	40.90%	38.30%	41.70%	N/A	N/A	38.10%	41.50%
CES	38.60%	28.30%	38.80%	27.70%	N/A	N/A	40.60%	32.20%
GHS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPIC-Norfolk	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
*data only available on early AMD								

Supplemental table 1. continued. Prevalence of any and late age-related macular degeneration (AMD) stratified by diabetes, use of anti-diabetic drugs, hyperlipidemia, and use of lipid-lowering drugs (LLD).

Study	Late AMD							
	No diabetes	Diabetes	No anti-diabetic drugs	Anti-diabetic drugs	No hyperlipidemia	Hyperlipidemia	No LLD	LLD
NICOLA	0.60%	2.10%	0.70%	1.60%	1.20%	0.60%	0.60%	1.20%
AugUR	7.20%	9.20%	7.40%	8.60%	N/A	N/A	7.80%	7.10%
EYERISK	6.70%	8.60%	5.10%	8.10%	19.40%	20.40%	7.60%	6.70%
UEMS	1.10%	1.50%	1.10%	0.90%	N/A	N/A	1.00%	1.10%
LIFE*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CES	2.50%	3.30%	2.50%	3.40%	N/A	N/A	3.40%	1.70%
GHS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPIC-Norfolk	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
*data only available on early AMD								